Skip to main content
. 2017 Jun 23;11:170. doi: 10.3389/fncel.2017.00170

Table 3.

Aberrant expression of miRNAs in fluids or blood cells of PD patients.

Studies Sources PD, n Ctrl, n Method Increased miRNA Decreased miRNA
Margis et al., 2011 Blood 81 8 qPCR miR-1, miR-22, miR-29a
Serafin et al., 2015 Blood 36 36 qPCR miR-29a, miR-30b, miR-103a
Soreq et al., 2013 Leukocytes 7 6 NGS miR-18b, miR-20a, miR-21, miR-150, miR-199b, miR-378c, miR-671, miR-1249, miR-1274b, miR-4293 miR-16, miR-92b, miR-320a, miR-320b, miR-320c, miR-769
Martins et al., 2011 PBMCs 19 13 M-array miR-19b, miR-26a, miR-28-5p, miR-29b, miR-29c, miR-30b, miR-30c, miR-126, miR-126, miR-147, miR-151-3p, miR-151-5p, miR-199a-5p, miR-199a/b-3p, miR-301a, miR-335, miR-374a, miR-374b
Cardo et al., 2013 Plasma 31 25 qPCR/TLDA2 miR-331-5p
Khoo et al., 2012 Plasma 42 30 qPCR/M-array2 miR-222, miR-505, miR-626
Li et al., 2017 Plasma 60 60 qPCR miR-137 miR-124
Current study, 2017 Plasma 46 49 qPCR miR-133b, miR-433
Burgos et al., 2014 Serum 50 62 NGS miR-30a-3p, miR-30e-3p, miR-338-3p miR-16-2-3p, miR-1294
Botta-Orfila et al., 2014 Serum 65 65 TLDA miR-19b, miR-29a, miR-29c
Cao et al., 2017 Serum 109 40 qPCR miR-24, miR-195 miR-19b
Ding et al., 2016 Serum 106 91 qPCR/S-seq2 miR-195 miR-15b, miR-181a, miR-185, miR-221
Dong et al., 2016 Serum 122 104 qPCR/S-seq2 miR-141, miR-146b-5p, miR-193a-3p, miR-214
Ma et al., 2016 Serum 138 112 qPCR miR-29c, miR-146a, miR-214, miR-221
Vallelunga et al., 2014 Serum 25 25 qPCR/TLDA2 miR-24, miR-223, miR-324-3p miR-30c, miR-148b
Zhao et al., 2014 Serum 46 46 qPCR miR-133b
Burgos et al., 2014 CSF 57 65 NGS miR-19a-3p, miR-19b-3p, let-7g-3p miR-10a-5p, miR-127-3p, miR-128, miR-132-5p, miR-136-3p, miR-212-3p, miR-370, miR-409-3p, miR-431-3p, miR-433, miR-485-5p, miR-873-3p, miR-1224-5p, miR-4448
Gui et al., 2015 CSF 78 35 qPCR/TLDA2 miR-10a-5p, miR-136-3p, miR-153, miR-409-3p, miR-433, let-7g-3p miR-1, miR-19b-3p
Marques et al., 2016 CSF 28 28 qPCR miR-205 miR-24

CSF, cerebrospinal fluid; Ctrl, controls; M-array, microarray; NGS, next generation sequencing; PBMCs, peripheral blood mononuclear cells; PD, Parkinson’s disease; S-seq, Solexa sequencing; TLDA, TaqMan Low Density Array; 1Untreated PD patients; 2qPCR as validation after initial screening using array or sequencing.